Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma.
Drees EEE, Roemer MGM, Groenewegen NJ, Perez-Boza J, van Eijndhoven MAJ, Prins LI, Verkuijlen SAWM, Tran XM, Driessen J, Zwezerijnen GJC, Stathi P, Mol K, Karregat JJJP, Kalantidou A, Vallés-Martí A, Molenaar TJ, Aparicio-Puerta E, van Dijk E, Ylstra B, Groothuis-Oudshoorn CGM, Hackenberg M, de Jong D, Zijlstra JM, Pegtel DM. Drees EEE, et al. Among authors: de jong d. J Extracell Vesicles. 2021 Jul;10(9):e12121. doi: 10.1002/jev2.12121. Epub 2021 Jul 15. J Extracell Vesicles. 2021. PMID: 34295456 Free PMC article.
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA. Roemer MG, et al. Among authors: de jong d. J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069084 Free PMC article.
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ. Roemer MG, et al. Among authors: de jong d. Cancer Immunol Res. 2016 Nov;4(11):910-916. doi: 10.1158/2326-6066.CIR-16-0201. Epub 2016 Oct 13. Cancer Immunol Res. 2016. PMID: 27737878 Free PMC article.
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients.
van Eijndhoven MA, Zijlstra JM, Groenewegen NJ, Drees EE, van Niele S, Baglio SR, Koppers-Lalic D, van der Voorn H, Libregts SF, Wauben MH, de Menezes RX, van Weering JR, Nieuwland R, Visser L, van den Berg A, de Jong D, Pegtel DM. van Eijndhoven MA, et al. Among authors: de menezes rx, de jong d. JCI Insight. 2016 Nov 17;1(19):e89631. doi: 10.1172/jci.insight.89631. JCI Insight. 2016. PMID: 27882350 Free PMC article.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: de jong d. Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7. Lancet Oncol. 2019. PMID: 30630772 Clinical Trial.
High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.
Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F, Janssen L, van der Schaaf A, Jansen E, Groenen PJTA, Eijkelenboom A, Stevens W, Hess CJ, van Krieken JH, Vermaat JSP, Cleven AHG, de Groen RAL, Neviani V, de Jong D, van Deventer S, Scheijen B, van Spriel AB. Elfrink S, et al. Among authors: de winde cm, de jong d, de groen ral. Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31. Blood. 2019. PMID: 31366619 Free PMC article.
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, Böhmer LH, Minnema MC, MacKenzie MA, van Marwijk Kooij R, de Jongh E, Snijders TJF, de Weerdt O, van Gelder M, Hoogendoorn M, Leys RBL, Kibbelaar RE, de Jong D, Chitu DA, Van't Veer MB, Kluin-Nelemans HC. Doorduijn JK, et al. Among authors: de jongh e, de weerdt o, de jong d. Br J Haematol. 2020 Aug;190(3):385-393. doi: 10.1111/bjh.16567. Epub 2020 Mar 9. Br J Haematol. 2020. PMID: 32150297 Free PMC article. Clinical Trial.
895 results